

Peptide receptor radionuclide therapy (PRRT) can be also considered as a personalized cancer therapy, as radio peptide can be altered into the unique biologic characteristics of the patient and the molecular properties of the tumor.
Peptide receptor radionuclide therapy (PRRT) is utilised in neuroendocrine tumours that express type 2 somatostatin receptors (sst2). The goal of this multi-cycle prospective phase I-II trial was to assess the toxicity and efficacy of 177Lu-DOTATATE.
Read More:
Click here for Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Report:
Click here for Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Press Release:





